- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Medicaid Work Requirements; Orphan Drug Designations; OUD Drug Gets Approved
Michigan’s plan to require Medicaid beneficiaries to show workforce engagement was approved by the Trump administration, while attorneys continue to challenge Arkansas’ own Medicaid work requirements; a new report from the Government Accountability Office has highlighted serious deficiencies with how the FDA administers the Orphan Drug Act; the FDA has granted tentative approval to a weekly and monthly treatment for moderate-to-severe opioid use disorder (OUD), but cannot grant final approval until another treatment’s exclusivity period ends.
More on States’ Medicaid Work Requirements
Michigan’s plan to require Medicaid beneficiaries to show workforce engagement was approved by the Trump administration. Able-bodied adults will have to show an average of 80 hours a month of engagement, which includes work, school, job training, community service, or substance abuse treatment, in order to keep their coverage, reported the Associated Press. The work requirements begin in 2020 and the waiver extends the program’s expansion through 2023. Meanwhile in Arkansas, attorneys continue to challenge the state’s Medicaid work requirements. The Associated Press also reported that the attorneys are citing the 17,000 people who lost coverage as evidence the requirements are a benefits cut, which is not allowed under federal law.
Trouble With Orphan Drug Designations
A new report from the Government Accountability Office (GAO) has highlighted serious deficiencies with how the FDA administers the Orphan Drug Act. According to The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, the report found that the FDA does not consistently ensure all required information is appropriately recorded and used in the regulatory decision-making process. GAO found that from 2008 to 2017, hematology and oncology drugs accounted for more than half of all orphan drug approvals.
Opioid Use Disorder Drug Gains Tentative Approval
The FDA has granted tentative approval to Braeburn’s Brixadi, a weekly and monthly treatment for moderate-to-severe opioid use disorder. Philadelphia Business Journal reported that the FDA cannot grant final approval until exclusivity for Indivior’s Sublocade expires in late 2020. Until that exclusivity ends, which could be challenged, Brixadi is not eligible for marketing in the United States. The same product was approved in November by the European Commission and the Australian Therapeutic Goods Administration to be marketed outside of the United States as Buvidal.
How Can Digital Care Programs Aid Those With Chronic Musculoskeletal Pain?
June 9th 2020On this episode of Managed Care Cast, we speak with Jeffrey Krauss, MD, chief medical officer of Hinge Health and Stanford Clinical assistant professor, about the efficacy of a 12-week digital care program aimed to reduce lower back and knee pain in a real-world population.
Listen
Understanding the Impact of Inappropriate Opioid Prescribing Practices
April 19th 2019Deaths from drug overdoses have become the leading cause of death for Americans under age 50, which can largely be attributed to prescription opioids. Due to the role of prescription opioids, understanding prescribing patterns and identifying inappropriate prescribing are crucial for changing the course of the epidemic.
Listen
MBSR Reduced Pain Perception in Patients With Migraine
December 19th 2020The finding about mindfulness-based stress reduction (MBSR) was a secondary outcome of the double-blinded, randomized, placebo-controlled clinical trial. The primary outcome—a reduction in the frequency of migraines—was not reached.
Read More
